Browse PRKCI

Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Membrane Endosome Nucleus Note=Transported into the endosome through interaction with SQSTM1/p62. After phosphorylation by SRC, transported into the nucleus through interaction with KPNB1. Colocalizes with CDK7 in the cytoplasm and nucleus. Transported to vesicular tubular clusters (VTCs) through interaction with RAB2A.
Domain PF00130 Phorbol esters/diacylglycerol binding domain (C1 domain)
PF00564 PB1 domain
PF00069 Protein kinase domain
PF00433 Protein kinase C terminal domain
Function

Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway. Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor (NGF), acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters (VTCs). In human coronary artery endothelial cells (HCAEC), is activated by saturated fatty acids and mediates lipid-induced apoptosis.

> Gene Ontology
 
Biological Process GO:0001654 eye development
GO:0001754 eye photoreceptor cell differentiation
GO:0006612 protein targeting to membrane
GO:0006900 membrane budding
GO:0007009 plasma membrane organization
GO:0007015 actin filament organization
GO:0007043 cell-cell junction assembly
GO:0007163 establishment or maintenance of cell polarity
GO:0007423 sensory organ development
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0010720 positive regulation of cell development
GO:0010827 regulation of glucose transport
GO:0010828 positive regulation of glucose transport
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0014009 glial cell proliferation
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0016050 vesicle organization
GO:0018105 peptidyl-serine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0030010 establishment of cell polarity
GO:0031346 positive regulation of cell projection organization
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0034349 glial cell apoptotic process
GO:0034350 regulation of glial cell apoptotic process
GO:0034351 negative regulation of glial cell apoptotic process
GO:0035088 establishment or maintenance of apical/basal cell polarity
GO:0035089 establishment of apical/basal cell polarity
GO:0042063 gliogenesis
GO:0042461 photoreceptor cell development
GO:0042462 eye photoreceptor cell development
GO:0043297 apical junction assembly
GO:0043434 response to peptide hormone
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0045197 establishment or maintenance of epithelial cell apical/basal polarity
GO:0045216 cell-cell junction organization
GO:0045666 positive regulation of neuron differentiation
GO:0046323 glucose import
GO:0046324 regulation of glucose import
GO:0046326 positive regulation of glucose import
GO:0046530 photoreceptor cell differentiation
GO:0048193 Golgi vesicle transport
GO:0048194 Golgi vesicle budding
GO:0048592 eye morphogenesis
GO:0050769 positive regulation of neurogenesis
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051402 neuron apoptotic process
GO:0051962 positive regulation of nervous system development
GO:0060251 regulation of glial cell proliferation
GO:0060252 positive regulation of glial cell proliferation
GO:0061162 establishment of monopolar cell polarity
GO:0061245 establishment or maintenance of bipolar cell polarity
GO:0061339 establishment or maintenance of monopolar cell polarity
GO:0070555 response to interleukin-1
GO:0070830 bicellular tight junction assembly
GO:0070997 neuron death
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0072577 endothelial cell apoptotic process
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090003 regulation of establishment of protein localization to plasma membrane
GO:0090004 positive regulation of establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:0090596 sensory organ morphogenesis
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1903076 regulation of protein localization to plasma membrane
GO:1903078 positive regulation of protein localization to plasma membrane
GO:1903729 regulation of plasma membrane organization
GO:1903829 positive regulation of cellular protein localization
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904037 positive regulation of epithelial cell apoptotic process
GO:1904375 regulation of protein localization to cell periphery
GO:1904377 positive regulation of protein localization to cell periphery
GO:1904951 positive regulation of establishment of protein localization
GO:1990778 protein localization to cell periphery
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000353 positive regulation of endothelial cell apoptotic process
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004697 protein kinase C activity
GO:0005543 phospholipid binding
Cellular Component GO:0005923 bicellular tight junction
GO:0016324 apical plasma membrane
GO:0031252 cell leading edge
GO:0043209 myelin sheath
GO:0043218 compact myelin
GO:0043220 Schmidt-Lanterman incisure
GO:0043296 apical junction complex
GO:0045171 intercellular bridge
GO:0045177 apical part of cell
GO:0070160 occluding junction
> KEGG and Reactome Pathway
 
KEGG hsa04015 Rap1 signaling pathway
hsa04144 Endocytosis
hsa04390 Hippo signaling pathway
hsa04530 Tight junction
hsa04611 Platelet activation
hsa04910 Insulin signaling pathway
Reactome R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-421270: Cell-cell junction organization
R-HSA-162582: Signal Transduction
R-HSA-166520: Signalling by NGF
R-HSA-420029: Tight junction interactions
R-HSA-193704: p75 NTR receptor-mediated signalling
R-HSA-209543: p75NTR recruits signalling complexes
R-HSA-193639: p75NTR signals via NF-kB
Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRKCI and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PRKCI and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28574228CholangiocarcinomaInhibit immunityaPKC-ι induced EMT and immunosuppression by regulating Snail in vitro and in vivo, although aPKC-ι did not directly interact with Snail in coimmunoprecipitation experiments.
28698296Ovarian CarcinomaInhibit immunityPRKCI promotes immune suppression in ovarian cancer. Mechanistically, we show that the oncogenic activity of PRKCI relates in part to the up-regulation of TNFα to promote an immune-suppressive tumor microenvironment characterized by an abundance of myeloid-derived suppressor cells and inhibition of cytotoxic T-cell infiltration. In human ovarian cancers, high PRKCI expression also correlates with high expression of TNFα and YAP1 and low infiltration of cytotoxic T cells.
Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRKCI in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRKCI in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1260.684
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0510.971
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1750.858
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0540.871
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1260.939
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2840.895
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0380.927
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0520.973
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0150.993
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0360.976
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7320.665
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.070.414
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRKCI in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRKCI. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRKCI. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRKCI.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRKCI. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRKCI expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRKCI and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRKCI
Nameprotein kinase C, iota
Aliases PKCI; DXS1179E; nPKC-iota; PRKC-lambda/iota; aPKC-lambda/iota; atypical protein kinase C-lambda/iota; Protei ......
Chromosomal Location3q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRKCI collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PRKCI.
ID Name Drug Type Targets #Targets
DB00675TamoxifenSmall MoleculeAR, EBP, ESR1, ESR2, ESRRG, KCNH2, NR1I2, PRKCA, PRKCB, PRKCD, PRK ......16
DB03777Rbt205 InhibitorSmall MoleculePDPK1, PIM1, PRKCI3